Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 16 studies | 47% ± 20% | |
basal cell | 8 studies | 35% ± 19% | |
secretory cell | 3 studies | 16% ± 1% | |
club cell | 3 studies | 25% ± 5% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 1% | |
epithelial cell | 3 studies | 47% ± 20% |
Insufficient scRNA-seq data for expression of FGFR3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 99% | 9250.38 | 326 / 328 | 83% | 43.18 | 147 / 178 |
brain | 92% | 13954.62 | 2436 / 2642 | 88% | 93.81 | 620 / 705 |
liver | 80% | 4063.84 | 181 / 226 | 84% | 61.73 | 340 / 406 |
kidney | 75% | 4617.48 | 67 / 89 | 62% | 22.15 | 559 / 901 |
esophagus | 38% | 9620.81 | 555 / 1445 | 86% | 86.87 | 157 / 183 |
bladder | 43% | 4690.48 | 9 / 21 | 75% | 147.39 | 377 / 504 |
prostate | 39% | 2412.18 | 96 / 245 | 65% | 17.87 | 327 / 502 |
ureter | 0% | 0 | 0 / 0 | 100% | 81.69 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 96% | 156.41 | 43 / 45 |
intestine | 30% | 1358.85 | 285 / 966 | 66% | 23.72 | 348 / 527 |
lung | 22% | 782.88 | 127 / 578 | 66% | 58.69 | 762 / 1155 |
skin | 72% | 30488.75 | 1296 / 1809 | 8% | 8.83 | 36 / 472 |
uterus | 1% | 170.38 | 2 / 170 | 74% | 98.00 | 341 / 459 |
stomach | 4% | 142.80 | 16 / 359 | 63% | 27.43 | 181 / 286 |
breast | 9% | 367.02 | 40 / 459 | 48% | 23.23 | 534 / 1118 |
ovary | 0% | 0 | 0 / 180 | 28% | 11.16 | 120 / 430 |
thymus | 0% | 4.97 | 1 / 653 | 20% | 10.28 | 119 / 605 |
eye | 0% | 0 | 0 / 0 | 8% | 1.34 | 6 / 80 |
adrenal gland | 0% | 0 | 0 / 258 | 3% | 1.46 | 6 / 230 |
spleen | 1% | 62.37 | 2 / 241 | 0% | 0 | 0 / 0 |
adipose | 0% | 32.41 | 4 / 1204 | 0% | 0 | 0 / 0 |
heart | 0% | 6.78 | 2 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 29.40 | 3 / 1335 | 0% | 0 | 0 / 0 |
muscle | 0% | 9.75 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0048640 | Biological process | negative regulation of developmental growth |
GO_0042531 | Biological process | positive regulation of tyrosine phosphorylation of STAT protein |
GO_0060349 | Biological process | bone morphogenesis |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0000165 | Biological process | MAPK cascade |
GO_0002062 | Biological process | chondrocyte differentiation |
GO_0035988 | Biological process | chondrocyte proliferation |
GO_0007275 | Biological process | multicellular organism development |
GO_0070977 | Biological process | bone maturation |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0001958 | Biological process | endochondral ossification |
GO_0007267 | Biological process | cell-cell signaling |
GO_1902178 | Biological process | fibroblast growth factor receptor apoptotic signaling pathway |
GO_0033674 | Biological process | positive regulation of kinase activity |
GO_0030282 | Biological process | bone mineralization |
GO_0001501 | Biological process | skeletal system development |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0010518 | Biological process | positive regulation of phospholipase activity |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0003416 | Biological process | endochondral bone growth |
GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
GO_0008543 | Biological process | fibroblast growth factor receptor signaling pathway |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005925 | Cellular component | focal adhesion |
GO_0009986 | Cellular component | cell surface |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0030133 | Cellular component | transport vesicle |
GO_0005007 | Molecular function | fibroblast growth factor receptor activity |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005524 | Molecular function | ATP binding |
GO_0017134 | Molecular function | fibroblast growth factor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FGFR3 |
Protein name | Fibroblast growth factor receptor 3 isoform B Fibroblast growth factor receptor 3 IIIc isoform Fibroblast growth factor receptor Fibroblast growth factor receptor 3 (FGFR-3) (EC 2.7.10.1) (CD antigen CD333) Fibroblast growth factor receptor 3 Fibroblast growth factor receptor 3 isoform C Mutant fibroblast growth factor receptor 3 Fibroblast growth factor receptor 3 (EC 2.7.10.1) Fibroblast growth factor receptor (EC 2.7.10.1) |
Synonyms | JTK4 |
Description | FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling. . |
Accessions | Q96T36 A0A5P8NAS4 X5D2G8 I6LM06 A0A3S5WLI4 Q9NRB6 A0N9W0 Q96T34 ENST00000440486.8 [P22607-1] ENST00000481110.7 F8W9L4 Q96T35 ENST00000352904.6 [P22607-3] Q8NI15 ENST00000260795.8 A0A3S5XAL5 Q8NI16 Q0IJ44 A8E633 P22607 ENST00000507588.1 X5D9H5 ENST00000412135.7 A0A7I2RW32 ENST00000340107.9 [P22607-2] X5D2W2 |